Review
======

Introduction
------------

Maspin (mammary serine protease inhibitor), is a member of the serine protease inhibitor/non-inhibitor superfamily (serpin), like plasminogen activator inhibitors 1 and 2 and α1-antitrypsin. Maspin gene is located on chromosome 18q21.3--q23 and it was identified for the first time in 1994.

Maspin expression is down-regulated in breast, prostate, gastric and melanoma cancers but over-expressed in pancreatic, gallbladder, colorectal, and thyroid cancers suggesting that maspin may play different activity in different cell types. These conflicting observations might be explained by distinct subcellular localization of maspin in cancer cells (cytoplasmic, nuclear or both cytoplasmic-nuclear expression); by interactions with extracellular matrix and its structure and epigenetic modifications \[[@B1]-[@B4]\].

A characteristic feature of serpin structure, is a reactive center loop (RCL), a peptide stretch that is located 9--15 residues amino-terminal to the reactive site peptide bond. RCL allows the reactive site to present an optimal configuration for binding, and subsequent inhibiting target protease.

The conformational change is known as the "stressed-to-relaxed" transition. Maspin, however, contains a relatively short, divergent, not highly conserved, hydrophobic RCL not capable of undergoing this transition. Collectively, these properties place maspin into the non-inhibitorycategory of the large serpin superfamily and shift the focus away from attempting to identify a target protease as explanation for the biological activities of maspin (Figure [1](#F1){ref-type="fig"}) \[[@B5]-[@B7]\].

![The x-ray crystal structure of maspin.](2001-1326-2-8-1){#F1}

Another interesting aspect of Maspin pertains to the G α-helix (G-helix), an internal salt bridge or the P1 position of the reactive center loop. The Maspin G-helix is capable of an "open and closed" conformational change inducing redistribution of charged residues within the molecule.

An intact G-helix is absolutely required for the effect of maspin on cell migration, and the effect of the maspin protein can be mimicked by a short peptide corresponding to this structural element. Maspin and the G-helix in isolation are reliant on α1 integrins for their effects on cell migration \[[@B8]\].

Furthermore the action of maspin on cell migration needed a 15-mer G-helix peptide right direct binding to the β1 integrin subunit resulting in the inactivation of β1 integrins (Figure [2](#F2){ref-type="fig"}) \[[@B9]-[@B11]\].

![Maspin three-dimensional structure.](2001-1326-2-8-2){#F2}

In fact several studies showed that Maspin elicits changes in the expression of proteins associated with the actin cytoskeleton that predict a less motile and invasive phenotype and reduced metastatic spread. Moreover, RCL appears to mediate binding to a cell surface receptor that promotes cell adhesion to type I collagen and fibronectin \[[@B12],[@B13]\].

To confirm this maspin action time-lapse video microscopic studies showed that recombinant maspin dramatically also inhibited the lamellopodia extension and vectorial translation \[[@B14]\].

Since tumor metastasis requires the detachment and invasion of tumor cells through the basement membrane and stroma, selectively increased adhesion by the presence of maspin may contribute to the inhibition of tumor metastasis (Figure [3](#F3){ref-type="fig"}) \[[@B15]-[@B17]\].

![Mechanism of maspin function in most of human cancer.](2001-1326-2-8-3){#F3}

During the process of metastasis, there are consistent changes in gene expression. Studies of genes that are reduced or silenced have yielded surprising insights into in vivo mechanisms of regulating tumor metastasis. This review describes a tumor suppressor gene, Maspin, which is often silenced in cancer cells and exhibits suppressing activity against tumor growth and metastasis. Maspin has been shown to be involved in processes that are important to both tumor growth and metastasis such as cell invasion, angiogenesis, and more recently apoptosis. Hence, many efforts have been devoted to deciphering the molecular mechanism of maspin. While some insights have come from the protease inhibitory effect of maspin, more perceptive results on how maspin may function in suppressing tumor metastasis have come from studies of gene manipulation, protein interactions and global protein profiling \[[@B18]\].

Recent evidence indicates, however, that nuclear localization of maspin in cancer cells is necessary for its tumor suppressor activity and nuclear-localized maspin binds to chromatin are required to effectively prevent cells from metastasizing \[[@B19]\].

About subcellular distribution, Maspin is predominantly cytoplasmic but it also localizes to other cellular compartments and is secreted. Secreted Maspin could bind to extracellular matrix components. Alternatively, it is possible that maspin exerts its role only in the nucleus at the level of gene or chromatin regulation and thus indirectly affects the cell-matrix interaction or differentiation state and is released only as a consequence of cell damage or necrosis \[[@B20]-[@B27]\].

It has recently established that maspin is epigenetically regulated in tissue-specific way. Epigenetic changes of maspin expression involve cytosine methylation, histone, deacetylation, and chromatin accessibility causing loss of gene function \[[@B28]-[@B30]\].

Several studies showed that over-expression of maspin in gastric, pancreatic, and ovarian cancers results from promoter CpG demethylation. This clearly indicates that both methylation and demethylation of maspin promoter could regulate maspin gene expression and could guide the interpretation of overexpression/down regulation associated with negative prognosis. The promoter methylation of the maspin gene leads to gene silencing in several tumors such as breast, thyroid, skin, and colon cancer and it has been recognized as one of the most frequent mechanisms causing loss of gene function. It is noteworthy that in somatic tissues, the majority of CpG islands are methylated, and tumor cells have global DNA hypomethylation compared with their normal counterparts. Hypomethylation is involved in the progression from the premalignant to a fully developed malignancy and leads to activation of genes important for cancer development \[[@B31]\].

Breast cancer
-------------

Maspin is the only pro-apoptotic serpin implicated in apoptosis regulation in breast cancer. The intracellular maspin can translocate to the mitochondria to induce cytochrome *c* release and caspase activation or modulate expression of Bcl-2 family members \[[@B32]-[@B40]\].

In order to confirm maspin tumor suppressor function, several authors investigated in vitro maspin expression in different tissue, from normal gland to metastatic disease. Maspin expression appears to be reduced in advanced stages of breast cancer. In fact, a significant stepwise decrease in maspin expression (and in vascular endothelial growth factor (VEGF) expression) occurred in the sequence DCIS (Ductal Carcinoma In Situ)- invasive cancer -- brain-lymph-node-bone metastasis experiments. Myoepithelium, normal breast and fibrocystic change showed a strong maspin expression \[[@B41]-[@B43]\].

Even if Maspin absence emerges as an indicator of tumor progression and metastatic potential, recent studies showed that maspin expression was correlated with an aggressive phenotype in the breast cancer and with poor prognosis. Three hypothesis were thought for the aberrant expression of maspin in breast cancer cells: maspin gene alteration with loss of activity; a high intracellular density of maspin resulting in auto-inhibition of its function; myoepithelial cell differentiation in cancer cells could contribute to more aggressive phenotype. It is also important to investigate the different subcellular maspin expression. In fact nuclear staining was demonstrated to be significantly associated with better a prognosis than cytoplasmic staining \[[@B44],[@B45]\].

Umekita et al. and Kim et al. examined, 92 and 192 invasive ductal carcinomas respectively. They reported that maspin expression was frequently observed in invasive ductal carcinoma with an aggressive phenotype (i.e. high histological grade), and it was a strong indicator of a poor prognosis \[[@B46],[@B47]\].

Conversely, in order to define the significance of subcellular maspin location, Mohsin et al. performed a preliminary study assessing the associations of maspin with other established prognostic factors in invasive breast cancer. In a series of 1068 breast cancer maspin nuclear staining was significantly associated with good prognostic factors rather than cytoplasmic staining \[[@B48]\].

Furthermore the prognostic role of maspin was investigated by Umekita et al. and Lee et al. They examined maspin and p53 expression in 168 and 80 patients with invasive ductal carcinoma, respectively. Large tumor size, high histologic grade, positive p53 status, negative estrogen receptor or progesterone receptor status and poor prognosis were correlated with maspin expression \[[@B49]-[@B51]\].

Stark et al. and Maas et al., instead, investigated the potential correlations between maspin expression in primary tumor and in the metastatic sites. They showed that maspin expression is reduced in primary tumors and again decreased in metastasis \[[@B52],[@B53]\].

This finding adds maspin to the list of metastasis suppressor genes potentially involved in the spread of breast cancer metastases (Table [1](#T1){ref-type="table"}).

###### 

Maspin expression in breast cancer

  **Authors**      **Year**   **N. patients**                       **Maspin expression**                                 **Clinical pathological features/prognosis**
  ---------------- ---------- ------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
  Umekita et al.   2003       92 (invasive breast cancer)           18.5% positive maspin                                 Positive maspin in invasive breast cancer and DCIS = large tumor size, presence of comedo-necrosis and high grade
                              145 (Ductal Carcinoma In Situ)        9.6%positive maspin                                    
                              27 (atypical hyperplasia)             3.7% positive maspin                                   
                              94 (usual hyperplasia)                0%positive maspin                                      
  Kim et al.       2003       192 (stage I-II breast cancer)        34.4% positive maspin                                 Positive maspin in all type of invasive breast cancer = high grade
                                                                    36.4% positive maspin in invasive ductal carcinoma     
                                                                    7.1% positive maspin in invasive lobular carcinoma)    
  Mohsin at al.    2003       1068 (breast cancer)                  35% positive cytoplasm                                Positive cytoplasmic maspin = negative ER and PgR, high Mib, aneuploidy
                                                                    96% positive nucleus                                  Positive nuclear maspin = positive ER and PgR
  Umekita et al.   2002       168 (breast cancer)                   27.4% positive maspin                                 Positive maspin = 17.4% Large tumor size, 43.4% high grade, 65.2% negative ER and PgR, 43.4% positive p53 shorter PFS and OS
                                                                    72.6% negative maspin                                 Negative maspin = 9% large tumor size, 19.6% high grade 35.2% negative ER and PgR 20,5% positive p53, better PFS and OS
  Umekita et al.   2011       135 (triple negative breast cancer)   85.9% positive maspin                                 Positive maspin = 43.1% age ≤ 50 years, 80.2% high grade
                                                                    14.1% negative maspin                                 Negative maspin = 5.2% age ≤ 50 years, 42.1% high grade
  Lee et al.       2006       80 (breast cancer)                    31.3% positive maspin                                 Positive maspin = 24% large tumor size, 52% high grade, 80% negative PgR, Short PFS and OS
                                                                    68.7% negative maspin                                 Negative maspin = 7.2% large tumor size, 21.8% high grade, 41.8% negative PgR, better PFS and OS
  Stark et al.     2012       16 (metastatic breast cancer)         30% positive maspin in primary tumor                   
                                                                    13% positive maspin in brain metastasis                
  Maass et al.     2001       45 (breast cancer)                    64% positive maspin                                   17.7% of patients develop metastasis = 75% negative maspin
                                                                    36% negative maspin                                    

Nevertheless, further investigations are needed to clarify the real mechanism of the aberrant expression of maspin in breast cancer, also in order to use it as a prognostic marker in clinical practice.

Prostate cancer
---------------

In human prostate cancer, maspin expression consistently appears to be down-regulated at the critical transition from non-invasive, low grade to high grade prostate cancer. In particular, the loss of basolateral maspin expression in benign secretory cells, the dramatically up-regulation in High Grade Prostatic Intraepithelial Neoplasia and the progressively decrease in invasive cancer are associated with maspin capability to reduce tumor growth, osteolysis and angiogenesis. Furthermore, there is an evidence that maspin inhibits prostate cancer-induced bone matrix remodeling and induces prostate cancer glandular redifferentiation \[[@B54]-[@B61]\].

Lovric et al. examined 34 biopsies of prostatic carcinoma. Maspin resulted expressed in the cytoplasm of basal cells of normal prostatic glands, whilst normal luminal cells were inconsistently weakly positive and it was aberrant over-expressed in prostate cancer with a predominance of nuclear presence \[[@B62]\].

On the other hand, Riddick et al. and Machtens et al. analyzed gene expression and clinico-pathologic features in 44 and 84 patients with prostate cancer, respectively. Maspin expression was inversely correlated with the Gleason score and positively correlated with lower tumor stage, more differentiated grade and a lower p53 protein mutation \[[@B63],[@B64]\].

Zou et al. investigated Maspin expression in 97 prostate tumor specimens showing that tumor cells that exhibit histological response to neoadjuvant "hormonal treatment" showed Maspin expression. These data suggest that the androgen withdrawal may unmask Maspin expression in prostate cancer, which frequently lacks Maspin expression (Table [2](#T2){ref-type="table"}) \[[@B65]\].

###### 

Maspin expression in prostate cancer

  **Authors**            **Years**  **N. patients**      **Maspin expression**                         **Clinical features/prognosis**
  --------------------- ----------- -------------------- --------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  Lovric et al.            2010     34 prostate cancer   79% positive maspin with nuclear expression    
  Riddick et al.           2005     44 prostate cancer   Not found                                     Positive maspin = lower Gleason score
  Machtens et al.          2001     84 prostate cancer   58% positive maspin                           Positive maspin = OS: 78 months, PFS: 41 months, GIII-IV: 23%, N1/N2: 9% OS = 62 months, PFS = 26 months, GIII-IV = 48%, N1/N2 = 18%
  18% negative maspin                                                                                  
  Zou et al.               2002     97 prostate cancer   40.2% positive maspin                         Positive maspin = 91.7% partial response with neoadjuvant therapy
                                                         49.8% negative maspin                          

In conclusion, Maspin expression correlates with a better prognosis and may serve as a biomarker for prostate cancer cells responding to the androgen ablation therapy.

Bladder cancer
--------------

Recent evidences seem to correlate a low maspin expression in bladder tumors to an increased tumor cell growth both in vivo and in vitro. In particular, maspin expression was preserved in superficial bladder cancers but significantly decreased in invasive carcinomas. Within the group of invasive cancers, the authors found that maspin expression was associated with good prognosis.

Recently, Lockett et al. showed the essential role of maspin in epithelial homeostasis and that a sub-cellular location of maspin seems to reflect a distinct tumor progression pathway. In particular, the nuclear location of maspin seems to be associated with lower histological grade and longer recurrence free disease \[[@B65]-[@B79]\].

Acikalin et al. evaluated the clinical significance of maspin in patients with T1 bladder cancer. They showed that maspin expression was associated with a longer time to recurrence and progression-free survival (PFS) than maspin-negative group \[[@B80]\].

Furthermore Kramer et al. investigated the role of maspin in transitional cell carcinoma of the bladder as well as its prognostic impact. Specimens from 162 non-muscle invasive bladder cancer patients treated by transurethral resection were examined. They showed that a low maspin protein expression was correlated with a higher incidence of tumor progression and emphasized a possible clinical role of this novel tumor suppressor gene in transitional cell carcinoma of the bladder \[[@B81]\].

In another study, Friedrich et al. analyzed the expression patterns of maspin in 110 pTa/pT1 urothelial carcinoma of the bladder and compared them with microvessel density (MVD) evaluated by CD105 and CD34. They found a decreased Maspin expression in a large portion of pTa/pT1 bladder tumors and shorter PFS with an increase of MVD in maspin negative cancers \[[@B82]\].

Again, Sugimoto et al. evaluated maspin expression in 65 series of bladder cancer. Maspin expression was significantly correlated with the development of muscle invasive bladder cancer. Their contradictory results were explained by the fact that maspin could contribute to bladder cancer development through DNA methylation and histone deacetylation \[[@B83]\].

Another recent study, focused on the role of Maspin in squamous cell carcinoma (SCC) and transitional cell carcinoma (TCC) of urinary bladder.

In 134 bladder cancer patients, the relationship between clinico-pathological features and Maspin was examined and a high Maspin expression was found in low grade and advanced stage. These results indicated that Maspin expression might predict a better prognosis for bladder carcinoma and it could play a role in tumor progression \[[@B84]\].

Blandamura et al. evaluated, instead, maspin expression in 111 bladder urothelial papillary neoplasms. Their results showed that a strong expression of maspin is related to a better outcome of papillary neoplasms and this is apparently in contrast with the absence or reduced maspin staining observed in the tumors of a lower histological grade and at pTa stage. This was probably due to the fact that the lower grade papillary neoplasms do not induce maspin activation, whereas high-grade neoplasms exert maspin action in an attempt to restrict tumor aggressiveness. (Table [3](#T3){ref-type="table"}) \[[@B85]\].

###### 

Maspin expression in bladder cancer

  **Authors**         **Years**   **N. patients**                                                                  **Maspin expression**                                       **Clinical features/prognosis**
  ------------------- ----------- -------------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------
  Acikalin et al.     2012        68 (T1 bladder cancer)                                                           Not specified                                               Positive maspin = longer PFS and less recurrence
                                                                                                                                                                               Negative maspin = shorter PFS and more recurrence
  Kramer at al.       2010        162 (pTa-pT1 bladder cancer)                                                     75.9% positive maspin                                       Positive maspin = PFS: 46 months
                                                                                                                   24.1% negative maspin                                       Negative maspin = PFS: 18 months
  Friedrich et al.    2004        110 (pTa-pT1 bladder cancer)                                                     33.6% positive maspin                                       Positive maspin = PFS: 29 months, MVD: 17.7(CD34) and 6.0 (CD105)per field
                                                                                                                   66.4%negative maspin                                        Negative maspin = PFS: 23 months, MVD = 21.7 (CD34) and 4.2 (CD105)per field
  Sugimoto et al.     2004        65 (22 transurethral resection and 43 radical resection specimens)               18.2%positive maspin in transurethral resection specimens   Positive maspin = progression from invasive bladder cancer
                                                                                                                   51.2% positive maspin in radical resection specimens         
  Nehad et al.        2010        134 (56 squamous cell carcinoma (scc)and 78 transitional urinary bladder(tcc))   53.7% positive maspin (42.8% scc and 61.5% tcc)             Positive maspin = 91.7% low grade
                                                                                                                   46.3% negative maspin                                       Negative maspin = 54.8% high grade
  Blandamura et al.   2008        66 (48 pTa e 18 pT1)                                                             38% positive maspin                                         60.5% positive maspin have high grade
                                                                                                                   62% negative maspin                                         22.44% positive maspin have low grade

In conclusion, further studies are needed to define the role of maspin in clinical practice of bladder tumors.

Lung cancer
-----------

Several studies demonstrated that maspin inhibits the survival pathway by influencing the response to cell death in lung cancer cells \[[@B86]\].

Bircan et al. investigated maspin in 63 patients with different histological lung carcinoma. The mean percentage of maspin expression was significantly higher in squamous cell carcinoma and adenocarcinoma, than in small cell lung cancer (SCLC) \[[@B87]\].

Recently, in lung cancer, maspin biological functions have been linked to its subcellular localization. Specifically, a nuclear, opposed to a combined nuclear and cytoplasmic localization has been associated with increased survival in non-small cell lung cancer (NSCLC). Lonardo et al., Frey et al., Woenckhaus et al. and Hirai et al., examined 123 NSCLC, 80 adenocarcinoma, 487 tissue microarrays and 112 specimens, respectively. They found that squamous cell carcinoma showed the highest expression and almost exclusively a combined nuclear-cytosolic stain in early stage. In contrast, nuclear maspin alone, correlated with favorable clinico-pathologic features and improved prognosis especially in adenocarcinoma \[[@B88]-[@B90]\].

Recently our group showed that maspin expression, with nuclear or cytoplasmic localization, together with smoking history, represented prognostic factors in NSCLC. In particular a significant longer overall survival (OS) was seen in patients with higher compared with lower expression of nuclear maspin, and poorer OS was present in patients with a higher intensity of cytoplasmic staining \[[@B91]\].

In another recent study, Wu et al. analysed the expression of maspin in NSCLC and its relationship to vasculogenic mimicry (VM). A total of 160 specimens of NSCLC were considered in this study. The loss of maspin expression may contribute to the invasion and metastasis of NSCLC and it has a positive relationship to VM in NSCLC \[[@B92]\].

Again, Nakagawa et al., Katakuta et al. and Takanami et al. investigated 210 consecutive patients with stage I-IIIA NSCLC, 55 resected NSCLC patients and 181 patients with curatively resected NSCLC respectively. Enhanced maspin expression was found a significant and independent factor in predicting a favorable prognosis in lung squamous cell carcinoma (Table [4](#T4){ref-type="table"}) \[[@B93]-[@B95]\].

###### 

Maspin expression in lung cancer

  **Authors**         **Years**   **N. patients**                    **Maspin expression**                      **Clinical features/prognosis/predictive factors**
  ------------------- ----------- ---------------------------------- ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bircan et al.       2010        28 (squamous cell lung cancer)     89.3% positive maspin                       
                                  18 (lung adenocarcinoma)           77.8% positive maspin                       
                                  17 (small cell lung cancer)        52.9% positive maspin                       
  Lonardo et al.      2005        46 (squamous cell lung cancer)     100% positive maspin                       Positive maspin = almost exclusively nuclear position
                                  77 (lung adenocarcinoma)           93,5% positive maspin                      Positive nuclear maspin in squamous cell lung cancer = low grade, low proliferative rate, absence of invasion, negative p53 vs nuclear-cytoplasmic position.
  Frey et al. 2009    2009        80 (lung adenocarcinoma)           93.7% positive maspin                       
                                                                     62.6% positive nucleus                     Positive nuclear maspin = 36.6% proliferative rate, Stage I OS: 87.7 ± 6.9 months, 42.5% moderate and poor differantation, 25,5% p53+, 4.2% high VEGF
                                                                     37.3% positive cytoplasm - nucleus         Positive cytoplasmic maspin = 56.9%proliferative rate, Stage I OS: 58.7 ± 6.5 months, 71.4% moderate and poor differantation,53.5% p53+, 39.2% high VEGF
  Woenckhaus et al.   2007        487 (tissue microarrays)           72.3% positive maspin                       
                                                                     65.3% positive nucleus                     Positive nuclear maspin = 63.9% squamous cancer, 16.9%
                                                                     37.8% positive cytoplasm                   Positive cytoplasmic maspin = 78.2% squamous cancer, 6.8% adenocarcinoma adenocarcinoma
  Hirai et al.        2005        112 (non-small cell lung cancer)   55.3%positive maspin                       Positive maspin = 77.8% positive cytoplasm Stage III and 36.2% positive cytoplasm Stage I
                                                                     44.7% negative maspin                       
  Berardi et al.      2010        439 (non-small cell lung cancer)   85.6% positive maspin                      Positive maspin = longer OS
                                                                     22.8% positive nucleus                     Positive nuclear maspin = independent prognostic factor
                                                                     44% positive cytoplasm                     Positive cytoplasmic maspin = especially smokers, lower OS than nuclear position
                                                                     14.4% negative maspin                      Negative maspin = Lower OS
  Wu et al.           2012        160 (non-small cell lung cancer)   48.1% positive maspin                      Positive maspin = lower vasculogenic mimicry and microvessel density, longer OS, low Stage, low grade, low lymphnode metastasis
                                                                     51.9% negative maspin                      Negative maspin = higher vasculogenic mimicry and microvessel density, lower OS, high Stage, high grade, lymphnode metastasis
                                  20 (normal tissue)                 100% positive maspin                        
  Nakagawa et al.     2006        210(non-small cell lung cancer)    73.7% positive maspin in squamous cancer   Positive maspin = 70.1% 5-years OS
                                                                     26.3%negative maspin in squamous cancer    Negative maspin = 41.5% 5-years OS
  Katakura et al.     2006        55 (non-small cell lung cancer)    Not found                                  Positive maspin = 67.7% 5-years OS
                                                                                                                Negative maspin = 41.4% 5-years OS
  Takanami et al.     2008        181 (non-small cell lung cancer)   40.8%positive maspin                        
                                                                     65.7% positive maspin in squamous cancer   Positive maspin in squamous cell lung cancer = 52.2% 5-years OS
                                                                     34.3%negative maspin in squamous cancer    Negative maspin in squamous cell lung cancer = 24% OS 5 years OS
                                                                     22.8% positive maspin in adenocarcinoma     
                                                                     59.2% negative maspin                       

Ovarian cancer
--------------

An evidence that maspin can inhibit ovarian cancer invasion has been shown in vitro, nevertheless the role of maspin in ovarian cancer remains to be demonstrated. However it seems that maspin expression level is low on normal ovarian surface epithelium, while ovarian cancer cell lines expressed high to low level of maspin expression that is also correlated with shorter survival in patients with epithelial ovarian cancer. Maspin expression was predominantly located in the cytoplasm and occasionally in the nucleus of epithelium and cancer cells \[[@B96],[@B97]\].

Klasa-Mazurkiewicz at al. examined 168 ovarian tissue and found maspin level significantly higher in patients with borderline tumors and early stages ovarian cancers when compared with healthy tissues those with benign and metastatic tumors. Over-expression of maspin was found to correlate with early stage of disease in non-serous subtypes of ovarian cancer and with a positive response to chemotherapy. A statistically significant longer PFS was observed in women with high as compared with low expression of maspin. Again Moshira et al. examining 68 ovarian specimens: 7 normal tissue, 18 benign, 14 borderline, 46 malignant epithelial ovarian neoplasm, detected the same results about progression disease \[[@B98]\].

As well as in other tumor types, also in ovarian cancer it is important its localization inside the cell in order to define the role of maspin.

Sopel et al. and Solomon et al. studied 132 and 11 invasive epithelial ovarian carcinomas, respectively. Cytoplasmatic maspin expression was correlated with worse clinico-pathologic features and prognosis rather than rare nuclear maspin expression \[[@B99],[@B100]\].

Few studies compared maspin with VEGF in ovarian carcinoma. In a recent study, over-expression of maspin, VEGFC, and VEGFD was significantly associated with unfavorable clinico-pathologic features and poor prognosis in 60 ovarian carcinoma tissues. Similar results were obtained by Sood et al. that assessed maspin expression in 104 ovarian tissue specimens \[[@B101]\].

Bauerschlag et al. investigated the prognostic role of maspin expression in 87 ovarian cancer specimens. There was significant correlation between cytoplasmic maspin expression and OS. Docetaxel- and paclitaxel-resistant ovarian cell lines showed an even higher level of maspin expression, suggesting an unfavorable role of cytoplasmic maspin in ovarian cancer (Table [5](#T5){ref-type="table"}) \[[@B102]\].

###### 

maspin expression in ovarian cancer

  **Authors**                 **Years**   **N. patients**                     **Maspin expression**                                                                                            **Clinical features/prognosis**
  --------------------------- ----------- ----------------------------------- ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Klasa-Mazurkiewicz et al.   2009        76 (ovarian cancer)                 82.9% positive maspin                                                                                            Positive maspin = OS and PFS longer than maspin negative tumor.
                                          8(Krukemberg tumor)                 87.2% positive maspin                                                                                             
                                          10 (borderline)                     90% borderline                                                                                                    
                                          42(benign tumor)                    78.6% positive maspin                                                                                             
                                          32(normal tissue)                   53.1% positive maspin                                                                                             
  Moshira et al.              2005        46(ovarian cancer) 14(borderline)   65.9% positive maspin = 69% positive cytoplasm, 3.4% positive nucleus and 27.6% positive nucleus and cytoplasm    
                                          18(benign tumor)                    57.1% positive maspin = 37.5% positive cytoplasm and 62.5% positive nucleus and cytoplasm                         
                                                                              100% positive cytoplasm                                                                                           
  Sopel et al.                2010        132 (ovarian cancer)                88.6% positive maspin                                                                                             
                                                                              22% positive nucleus                                                                                             Positive nuclear maspin = low tumor grade, less distant metastasis, low Figo stage, longer OS
                                                                              12.9% positive cytoplasm                                                                                         Positive cytoplasmic maspin = high tumor grade, probably distant metastasis, high Figo stage, shorter OS
  Solomon et al.              2006        118 (serous ovarian cancer)         81.4% positive maspin                                                                                             
                                                                              21.2% positive nucleus                                                                                           Positive nuclear maspin = lower VEGF and COX-2, OS:1803 days
                                                                              60.2% positive cytoplasm                                                                                         Positive cytoplasmic maspin = higher VEGF and COX-2, OS:637 days
                                                                              18.6% negative maspin                                                                                            Negative maspin = OS:1146 days
  Bolat et al.                2008        60 (ovarian cancer)                 88.3% positive cytoplasm                                                                                         Positive maspin = high VEGF, high grade, high clinical stage, ascite, lymphnode methastasis
                                                                              11.7% positive nucleus--cytoplasm                                                                                 
  Sood et al.                 2002        80(ovarian cancer)                  71% positive maspin                                                                                              Positive maspin = shorter OS, 63.3% high grade and 90% ascite
                                          10 (borderline)                     26.6% positive nucleus                                                                                           Positive nuclear maspin = longer OS
                                          14 (benign tumor)                                                                                                                                     
  Bauerschlag et al.          2010        87 (ovarian cancer)                 Not found                                                                                                        Positive maspin = OS: 28 months and platinum-therapy resistance
                                                                                                                                                                                               Negative maspin = OS: 57 months

Colorectal cancer
-----------------

Maspin has been investigated for its hypothetic implication in the cancerogenesis of colorectal cancer, for its probable association with conventional histo-pathological features and for its potential as an independent predictor of survival and response to adjuvant chemotherapy.

Cao et al. investigated the relationship between chronic inflammatory states and neoplasia in 125 specimens included inflammatory bowel disease (IBD) with different grade of dysplasia and also with invasive colorectal cancer. Maspin was found paradoxically over-expressed in both active IBD and colitis-associated dysplasia compared to either inactive IBD or normal colonic mucosa, suggesting a potential role in disease "flare" as well as neoplastic progression \[[@B103]\].

Other recent studies demonstrated a sequential decreased expression rate from adenoma to metastatic colorectal carcinomas and an inverse correlation with p53 and microvessel density \[[@B104]-[@B106]\].

Focusing on the clinico-pathologic features associated with maspin, Umekita et al. studied expression of maspin in colorectal adenocarcinomas from 104 patients and observed that maspin was significantly correlated with the depth of invasion, higher Dukes' classification and high-grade tumor budding. These results suggest that the expression of maspin may correlate with the aggressiveness of colorectal adenocarcinomas \[[@B107]\].

On the other hand, Fung et al. examined 450 resected colorectal cancer finding a stronger expression in right than in left-sided tumors and a stronger expression in high-grade tumors \[[@B108]\].

Regarding relationship between maspin, other biomarker and a possible target therapy, Gurzu at al. evaluated maspin, p53 and other biomarker expression in 110 cases with colorectal cancer with the aim to correlate maspin with angiogenesis and 5-Fluorouracil (5-FU) therapy. They found a correlation with tumor stage and microsatellite status. Therefore maspin nuclear expression, associated with p53 ones, might be used either to select the high-risk microsatellite stable (MSS) colorectal carcinomas diagnosed in Stage II or those MSI cases which can respond to 5-FU \[[@B109]\].

In another recent study on 156 colorectal cases, significant correlations between cytoplasmic expression and high tumor grade and between nuclear expression, high tumor budding and worse OS, were shown. These findings suggest a compartment-dependent function of maspin in colorectal cancer, which can be useful in identifying stage II cases with a higher risk for fatal outcome with a possible benefit from adjuvant chemotherapy \[[@B110]\].

Again Dietmaier et al. investigated nuclear maspin expression in 172 primary stage III colon cancers showing a significant treatment benefit from 5-FU-based chemotherapy in patients with primary tumors expressing Maspin in the nucleus. These data could be useful, if confirmed in a prospective study, to select patients to receive 5-FU treatment or an alternative (non-5-FU based) adjuvant therapy regime (Table [6](#T6){ref-type="table"}) \[[@B111]\].

###### 

Maspin expression in colorectal cancer

  **Authors**                                             **Years**                                                 **N. patients**                                                             **Maspin expression**                                **Clinical features/prognosis/predictive factors**
  ------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  Cao et al.                                              2005                                                      25 (colorectal cancer and IBD)                                              88%positive maspin                                    
  51 (active chronic IBD)                                 92% positive maspin                                                                                                                                                                        
  30 (inactive chronic IBD)                               43% positive maspin                                                                                                                                                                        
  9(normal mucosa)                                        11% positive maspin                                                                                                                                                                        
  Song et al.                                             2002                                                      66 (colorectal cancer)                                                      75.5% positive maspin                                Positive maspin in colorectal cancer = 44.7% mutant p53 expression, microvessel density = 181.1+/−54.2
  24(adenoma)                                             24.5% negative maspin                                     Negative maspin in colorectal cancer = microvessel density = 256.1 +/75.4                                                        
  91.7% positive maspin                                                                                                                                                                                                                              
  Positive maspin in adenoma = 0% mutant p53 expression                                                                                                                                                                                              
  Jiang-tao et al.                                        2009                                                      50 (colorectal cancer)                                                      62% positive maspin                                  Positive maspin in colorectal cancer = no association with positive lymphnode, higher Duke's stage or mutant p53 expression
  20 (adenoma)                                            90% positive maspin                                                                                                                                                                        
  20 (normal mucosa)                                      95%positive maspin                                                                                                                                                                         
  Zheng et al.                                            2007                                                      119 (colorectal cancer)                                                     95% positive maspin                                  Positive maspin in colorectal cancer = no liver metastasis = 89% positive maspin
  22 (adenoma)                                            93%positive maspin                                                                                                                                                                         
  118 (normal mucosa)                                     69%positive maspin                                                                                                                                                                         
  Umekita et al.                                          2006                                                      104 (colorectal cancer)                                                     66%positive maspin (15% = T1-T2 and 78.5% = T3-T4)   Positive maspin = 44.2% absent tumor budding, 32.7% Duke's stage B
  Fung et al.                                             2010                                                      450 (colorectal cancer)                                                     81%positive cytoplasm 80% positive nucleus           Positive maspin = right colon and high-grade tumor
  Gurzu et al.                                            2012                                                      101 (colorecatal cancer)                                                    60% positive maspin                                  Positive maspin = Stage II-III
  Markl et al.                                            2010                                                      156 (colorectal cancer stage I-II)                                          48% positive nucleus                                 Positive nuclear maspin = pT3 OS = 40 months
  72% positive cytoplasm                                  Positive cytoplasmic maspin = pT3 OS = 63 months                                                                                                                                           
  Dietmaier et al.                                        2006                                                      172 (colorectal cancer)                                                     44.4% negative nucleus                               Negative nuclear maspin = OS: 79.2%, OS after 5FU: 32.5%
  55.6% positive nucleus                                  Positive nuclear maspin = OS:66.6%, OS after 5FU: 71.7%                                                                                                                                    
  24.1% negative cytoplasm                                                                                                                                                                                                                           
                                                                                                                                                                                                75.9% positive cytoplasm                              

Gastric cancer
--------------

In human gastric cancer the molecular aspect of carcinogenesis and progression remains elusive. Data are very few but it seems that maspin up-regulation may cause a retarding cell proliferation \[[@B112]\].

Wang et al. investigated maspin expression in 113 gastric cancer and compared it with clinical parameters, MVD and Caspase-3 expression. Cancer less frequently expressed maspin than normal mucosa and dysplasia. Maspin expression showed a significantly negative correlation with invasive depth, metastasis, Lauren's and Nakamura's classification and MVD, but a positive correlation with expression of Caspase-3 in gastric cancer \[[@B113]\].

In another recent study in 152 cases of gastric cancer, an inverse relationship between maspin and p53 expression was documented. Moreover maspin expression showed a negative association with histologic grade, depth of invasion, metastasis, and TNM stage. Interestingly, patients with nuclear and cytoplasmic maspin expression presented a longer survival than those with only cytoplasmic expression (Table [7](#T7){ref-type="table"}) \[[@B114]\].

###### 

maspin expression in gastric, pancreatic and gallbladder cancer

  **Authors**                                  **Years**                                                                                       **N. patients**            **Maspin expression**   **Clinical features/prognosis/predictive factors**
  -------------------------------------------- ----------------------------------------------------------------------------------------------- -------------------------- ----------------------- -----------------------------------------------------------------------------------------------
  Wang et al.                                  2004                                                                                            113 (gastric cancer)       50.5% positive maspin   Positive maspin = T4: 35.9%, metastasis: 34.3%, subtype diffuse: 42.1%, undifferentiated: 40%
  49.5% negative maspin                        Negative maspin = T4: 64.1%, metastasis: 65.7%, subtype diffuse: 57.9%, undifferentiated: 60%                                                      
  Lee et al.                                   2008                                                                                            152 (gastric cancer)       71.7% positive maspin    
  29.3% negative maspin                        Negative maspin = undifferentiated, high stage, metastasis and invasion depth, positive p53                                                        
  Liu et al.                                   2012                                                                                            102 (pancreatic cancer)    98% positive maspin      
  Maas et al.                                  2001                                                                                            24 (pancreatic cancer)     96% positive maspin      
  5 (PanIn3)                                                                                                                                                                                      
  100% positive maspin                                                                                                                                                                            
  Maesawa                                      2006                                                                                            69 (cholelithiasis)        14% positive maspin      
  14 (cholelitiasis + intestinal metaplasia)                                                                                                                                                      
  64%positive maspin                                                                                                                                                                              
  Kim et al.                                   2012                                                                                            101 (gallbladder cancer)   59.4% positive maspin    
  25(adenoma)                                  100% negative maspin                                                                                                                               
  10 (normal gallbladder)                                                                                                                                                                         
                                                                                                                                                                          100%negative maspin      

On the basis of all the above mentioned results, Maspin expression could be considered as an effective and objective marker to reveal biological behaviors of gastric cancer and it could become an useful marker in the future.

Pancreatic cancer
-----------------

Unlike other malignant tumors, precancerous pancreatic lesions and pancreatic cancer present up-regulation of maspin gene expression, therefore maspin could be considered a new factor associated with pancreatic cancer. Liu et al. and Maass at al. examined 102 and 29 specimens of pancreatic tissue and demonstrated that more than 90% of cases of ductal adenocarcinoma as well as all high-grade precancerous lesions (PanIN3) were positive for maspin, and normal pancreatic ducts and low-grade precancerous lesions were usually negative for maspin (Table [7](#T7){ref-type="table"}) \[[@B115]\].

These data show that maspin may play an important role in the carcinogenesis, tumor invasion, metastasis, and angiogenesis of pancreatic cancer. Its relationship to carcinoma of the pancreas opens a new angle to the discussion on its function in cancer \[[@B116]\].

Gallbladder cancer
------------------

There are few published data focusing on maspin expression in gallbladder cancer, but there is an evidence of maspin implication in cholelithiasis-intestinal metaplasia-dysplasia-carcinoma sequence and in the early step of gallbladder cancerogenesis.

In a recent study on 69 patients with cholelithiasis and 30 patients with gallbladder cancer without cholelithiasis, a positive immunoreactivity for maspin was significantly associated with the presence of intestinal metaplasia in patients with cholelithiasis. These data could support the assumption that intestinal metaplasia of the gallbladder may predispose to gallbladder carcinoma \[[@B117]\].

Furthermore Kim et al. compared the pattern of maspin expression in 101 early and advanced gallbladder cancers. The positivity of maspin expression was found almost in half of gallbladder cancers, whereas no maspin was expressed in adenomas and normal mucosa of gallbladder (Table [7](#T7){ref-type="table"}) \[[@B118]\].

Head and neck cancer
--------------------

Maspin seems to be an important prognostic factor also in head and neck cancer. In particular some studies revealed that the subcellular location seems to make the difference. Nuclear expression is a positive prognostic factor rather than cytoplasmic location \[[@B119],[@B120]\].

Yoshizawa et al. and Iezzi et al. investigated the possible correlation between clinico-pathologic findings and maspin expression in 54 and 89 oral squamous cell carcinoma, respectively. Maspin was associated with a better survival rate, but a negative correlation with type of invasion, T-stage, lymph-node metastasis and differentiation grade was found \[[@B121]-[@B123]\].

Furthermore the cytoplasmic localization was significantly associated with a high risk of disease disseminating to neck lymph-nodes in 56 consecutive cases of oral carcinoma and the nuclear expression was correlated with lower loco-regional recurrence rate and a longer disease-free survival after treatment in elderly patient with laryngeal carcinoma (Table [8](#T8){ref-type="table"}) \[[@B124],[@B125]\].

###### 

maspin expression in head and neck cancers

  **Authors**                       **Year**                                            **N. patients**         **Maspin expression**   **Clinical pathological features/prognosis**
  --------------------------------- --------------------------------------------------- ----------------------- ----------------------- ----------------------------------------------------------------------------------------------
  Yoshizawa et al.                  2011                                                54 (OSCC)               64.8% positive maspin   Positive maspin = 77.8% OS
  35.2% negative maspin             Negative maspin = 29.4% OS                                                                          
  Yoshizawa et al.                  2009                                                71 (OSCC)               64.8% positive maspin   Positive maspin = 100% low grade, 93.3% no lymphnode metastasis, better OS
  Iezzi et al.                      2007                                                89 (OSCC)               Not found               Positive maspin = low grade, negative lymphnode, high stage(?)
  Marioni et al.                    2008                                                56 (OSCC)               58.9% positive maspin    
  5.3 % positive nucleus                                                                                                                
  1.8% positive cytoplasm-nucleus                                                                                                       
  51.8% positive cytoplasm          Positive cytoplasmic maspin = 61% pN0 and 33% pN+                                                   
  41.1% negative maspin                                                                                                                 
  Marioni et al.                    2011                                                68 (laryngeal cancer)   Not found               Positive nucleus = 22.7% lower recurrence and PFS: 44.5 ± 27.5 months
                                                                                                                                        Positive cytoplasm and cytoplasm-nucleus = 44.6% longer recurrence and PFS: 34 ± 27.5 months

In conclusion, maspin may represent an useful marker to identify the potential for progression of head and neck cancer, since lower immunoreactivity is associated with larger tumors and a greater invasive potential. Furthermore in head and neck cancer it is necessary to clarify the mechanisms between maspin expression and progression of tumor in order to apply to clinical applications.

Thyroid cancer
--------------

Maspin expression was investigated also in thyroid neoplasms originating in follicular cells. Some studies showed that neither normal follicular cells nor stromal cells expressed maspin. Papillary and follicular carcinomas expressed maspin in significantly higher incidence than those with pure papillary or follicular patterns. These findings indicate that maspin expression is directly associated with prognosis in this setting \[[@B126]\].

Boltze et al. and Tahany et al. detected maspin in 230 and 63 different histological thyroid tissue, respectively, showing that its expression was typical of papillary thyroid tumor, it was associated with tumor multicentricity, vascular and lymphatic invasion, as well as lymph-node metastasis and it was weakly expressed in follicular cancer and absent in normal tissue and in undifferentiated cancers. Maspin expression is a special feature of papillary thyroid carcinomas; promotor methylation-caused maspin repression plays a major role in gene balance and in the process of tumor determination. Therefore maspin could possibly act as a clinically relevant inhibitor of tumor progression, preventing local invasiveness and further systemic progression of papillary thyroid carcinomas \[[@B127],[@B128]\].

Data regarding the relation between maspin expression and clinico-pathological parameters need to be further confirmed on a larger scale with a longer follow up of patients in order to evaluate its relationship with clinical outcome including OS, disease free survival as well as tumor recurrence (Table [9](#T9){ref-type="table"}) \[[@B129]\].

###### 

Thyroid cancer and melanoma

  **Authors**      **Years**        **N. patients**         **Maspin expression**  **Clinical features/prognosis/predictive factors**
  --------------- ----------- ---------------------------- ----------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Boltze et al.      2004      68 (papillary carcinomas)    70.5% positive maspin  Positive maspin in papillary cancer = 2% p53+, 83% 110 months OS, Recurrence free disease: 60 months
                               38 (follicular carcinomas)   100% negative maspin   Negative maspin in follicular carcinomas = 80%p53+, 40% 110 months OS, Recurrence free disease :40months
  Tahany et al.      2006        63(thyroid specimes)=      28.5%positive maspin   Positive maspin = 72% papillary thyroid, 61,1% positive cytoplasm and positive nucleus, 11.1 % positive nucleus and 27.8% positive cytoplasm,
                                 25 papillary carcinoma     71.5% negative maspin   
  Wada et al.        2004       45 (malignant melanoma)     12.5% positive maspin   
                                                            87.5% negative maspin  Negative maspin in melanoma = 83% trunk, 89% extremites, 89% acral, 86% lentigo maligna melanoma, 100% nodular melanoma, 75% superficial spreading, 100% thickness 1.0-4.0 and \>4 mm, 100% II-III-IV stage
  Chua et al.        2009        77(malignant melanoma)     59.7% positive maspin  Positive maspin = less microvessel density, 78% thin melanoma, 46% thick melanoma
                                                            35.1% negative maspin  Negative maspin = high microvessel density, 22% thin melanomas, 54% thick melanoma

Melanoma
--------

In melanoma, Maspin was found to have a tumor-suppressor function. Previous reports showed that early hypermethylation of the Maspin promoter might play a role in silencing Maspin. In particular Maspin promoter activity was significantly increased after the thrombin receptor protease activated receptor-1 (PAR-1) silencing, suggesting that PAR1 negatively regulates Maspin at the transcriptional level Maspin tumor-suppressor gene in the acquisition of the metastatic melanoma phenotype \[[@B130]-[@B133]\].

Wada et al. investigated maspin expression in five melanoma cell lines, in a normal human epidermal melanocyte cell line, and in 80 surgically resected tumors. Their results suggest that maspin expression in normal skin melanocytes and melanocytic nevi may be repressed, whereas maspin is aberrantly expressed in a subset of melanoma cells by epigenetic modification. In particular Chua et al. in 77 melanoma samples found maspin presence in the radial growth phase in melanoma, and a lost maspin expression in the transition from the radial growth phase to the vertical growth phase of melanoma (Table [9](#T9){ref-type="table"}) \[[@B134],[@B135]\].

Future perspectives
-------------------

The expression of maspin might be useful as a prognostic and possibly predictive factor for patients with particular types of cancer and data can guide physicians in selecting therapy. Its expression in circulating tumor cells especially in breast cancer, could be also useful in clinical practice along with other factors, such as age, comorbidities, blood examinations in order to select the best therapy to be carried out.

Detecting maspin mRNA amplification by RT-PCR, several authors, as mentioned above, showed maspin in normal breast epithelial cells and in primary and metastatic breast cells, but not in the peripheral blood of healthy donors. Furthermore, they found the presence of circulating maspin-positive cells, potentially neoplastic, in the peripheral blood of patients with breast cancer undergoing conventional-dose chemotherapy. On the basis of these observations, they assessed a possible mobilizing effect of chemotherapy, delivered at standard doses, on mammary cells of potential neoplastic origin. Thus suggesting that the detection of circulating breast cells could have prognostic significance, as it was associated with a higher risk of early relapse or disease progression for patients with limited or stage IV disease, respectively. The results of these studies should be interpreted with caution, and larger studies with longer follow-up are required to definitely establish the clinical usefulness of the test \[[@B136]-[@B139]\].

Moreover, maspin expression was found directly correlated with treatment including carboplatin plus vinorelbine combined with radiotherapy in primary head and neck squamous cell carcinoma \[[@B140]\].

In some cases, the subcellular localization could predict response to chemotherapy. In fact, nuclear maspin expression in patients with stage III colon cancer is associated with response to adjuvant 5-FU-based chemotherapy and could help to select patients whose tumors do not express this molecule that may be candidates for an alternative (non-5-FU-based) adjuvant therapy regimen.

Focusing on the malignancies in which maspin showed a positive prognostic value, therapeutic approaches studied so far aimed to re-activate a dormant tumor suppressor gene by designed transcription factors, to hit the system that inhibits the expression of maspin, to identify natural substances that can determine the activation and the expression of maspin or possible "molecules binds" to introduce maspin in cancer cell and gene therapy capable of up-regulating the maspin in an attempt to reduce primarily the risk of metastasis.

Some authors hypothesized that artificial transcription factors (ATFs), composed of modular zinc finger (ZF) domains and designed to recognize specific sequences in the promoter of a tumor suppressor, would result in a re-expression of the endogenous gene silenced by epigenetic mechanisms in aggressive tumor cells (e.g. in metastatic breast cancer and in non-small cell lung cancer) and also in up-regulation of E-cadherin. Reversal and modification of the tumor suppressor epigenetic state can be achieved by blocking DNA and histone methyltransferases as well as histone deacetylases with different doses of ATFs and chromatin remodeling drugs: the methyltransferase inhibitor 5-aza-2'-deoxycytidine and the histone deacetylase inhibitor suberoylanilide hydroxamic acid. It was found that ATFs act in synergy with inhibitors in reactivating endogenous maspin expression. The strongest synergy was observed with the combination treatment ATF-126 + 5-aza-2'-deoxycytidine + suberoylanilide hydroxamic acid. While drugs can be used to achieve the inhibition of these enzymes in an untargeted manner, the precise mechanisms and the genetic cascades whereby these drugs induce biological changes are currently not completely understood and it seems to depend on cell micro-environment. Furthermore, given that tumor suppressors sustain anti-proliferative and anti-metastatic functions, it is essential to target the native tumor suppressor function in order to develop more effective therapies.

Given the clinical relevance of maspin expression in a variety of epithelial tumors (including breast, prostate, lung and colon cancer), these studies describe a novel approach to target multiple human tumors \[[@B141]-[@B148]\].

Recently, PAR-1 has been described to regulate the gap junction protein Connexin 43 and the maspin tumor suppressor gene to promote the metastatic melanoma phenotype. Silencing PAR-1 results in decreased activation of p38 MAPK, allowing for increased binding of c-Jun and Ets-1 transcription factors to the maspin promoter. Increased Maspin expression further inhibits cell invasion, through decreased expression and activity of MMP-2, as well as angiogenesis through decreased VEGF expression \[[@B149]\].

An important role of IL-6TS in decreasing adhesion and increasing motility and migration in prostate cancer, along with its effect on the inhibition of maspin was also found. Therefore, specific targeting IL-6TS in prostate cancer patients, might represent an interesting way to refine the currently available experimental anti-IL-6 therapies since sIL-6R and IL-6 are altered in patients with a worse prognosis. This information may be helpful to identify those patients who could benefit from the anti-cytokine therapy \[[@B150]\].

Recent studies have investigated the use of maspin as a therapeutic agent against cancer. In one study, maspin was found to inhibit cancer growth and metastasis in a breast cancer mouse model through a maspin DNA-liposome therapy. Another study showed the ability of maspin to induce apoptosis in tumor-specific endothelial cells. Taken together, these studies demonstrate the potential use of maspin as a viable anticancer therapeutic agent \[[@B151]\]. Gene therapy focusing on the use of adeno-associated virus (AAV, serotype 2) vector encoding maspin in human prostate cancer was also evaluated. Immunofluorescence double staining for maspin protein and apoptosis in LNCaP tumors showed that the percentage of apoptotic cells in AAV-maspin-mediated maspin-expressing cells was significantly high if compared with that in AAV-GFP-mediated GFP-expressing cells. Moreover, significantly fewer CD31-positive microvessels were observed in AAV-maspin-treated tumors compared with the control tumors. These therapeutic responses were highly correlated to persistent maspin expression in tumors, confirmed by Western blot analysis until at least 56 days after treatment. Furthermore AAV-mediated prolonged maspin expression efficiently suppresses human prostate tumor growth in vivo by apoptosis induction and inhibition of angiogenesis \[[@B152]\].

Focusing on natural substances, it has been showed that curcumin, a hydrophobic polyphenol derived from turmeric (the rhizome of the herb Curcuma longa), is implicated in the inhibition of tumorigenesis with a combination of anti-inflammatory, anti-oxidant, immunomodulatory, pro-apoptotic, and anti-angiogenic properties via pleiotropic effects on genes and cell-signaling pathways at multiple levels, including activation of transcription factors, receptors, kinases, cytokines, enzymes and growth factors.

When curcumin is combined with some cytotoxic drugs or certain other diet-derived polyphenols, synergistic effects have been demonstrated \[[@B153]-[@B155]\].

Curcumin has recently received a great deal of attention as a chemoprotective agent for the prevention of colon and breast cancer and it may have clinical application in the prevention of prostate cancer. Curcumin down-regulates the androgen receptor gene not only at the protein level but also in its transcriptional activity in androgen-depended prostate cancer. The suppression of androgen receptor transaction may affect the androgen receptor regulated genes such as maspin and curcumin increase the expression of maspin with dose and time dependence.

The mechanism utilized by curcumin to up-regulate maspin expression is unknown at this time. Nevertheless, the up-regulation only occurs in cells that have wild-type p53. This suggests that the activity of curcumin toward maspin expression may be modulated through the p53 pathway. Two other examples of nutritional compounds that have been reported to enhance tumor suppression and inhibit metastasis through up-regulation of maspin are abalone visceral extract and apple peel extract.

As in the case of curcumin, the cells treated with apple peel extract displayed significant increases in the expression of maspin \[[@B156]-[@B158]\].

Also resveratrol (trans-3, 49, 5-trihydroxystilbene), a polyphenolic antioxidant found in peanuts, grapes and red wine possesses significant health benefits. This compound has shown beneficial effects in experimental cancer models, where it suppresses the initiation, promotion and progression of tumors Recent studies have implicated activation of the apoptotic pathway as a mechanism accounting for the antitumor benefits of resveratrol. For example, resveratrol inhibits cell proliferation, induces apoptosis of human prostate carcinoma and acute lymphoblastic leukemia cells and increases maspin levels through Akt pathway \[[@B159]-[@B163]\].

Conclusion
==========

It is important to continue to search for the maspin in different tumor types in order to better define its prognostic significance, to refine the definition techniques of cellular compartmentalization and to evaluate the possible therapeutic implications considering peculiarities of expression of maspin in various cancers (Table [10](#T10){ref-type="table"}).

###### 

summary of maspin expression

  **Cancer**                                               **Tumor progression normal to cancer**                                                                      **Positive cytoplasm or positive nucleus**                                              **Prognosis**
  -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  Breast cancer                                            Normal tissue: positive maspin                                                                              Positive nucleus = better prognosis                                                     Positive maspin = better/worse prognosis depending of localization and of epigenetic modification
  Cancer tissue +/−                                                                                                                                                                                                                                            
  Cancer metastasis = negative maspin                                                                                                                                                                                                                          
  Prostate cancer                                          Normal tissue:                                                                                              Positive nucleus increased in invasive cancer                                           Positive maspin = better prognosis
  Negative maspin                                                                                                                                                                                                                                              
  HGPI: positive maspin                                                                                                                                                                                                                                        
  Invasive cancer = negative maspin                                                                                                                                                                                                                            
  Bladder cancer                                           Normal tissue:                                                                                              Positive nucleus = better prognosis                                                     Positive maspin = better prognosis
  Positive maspin                                                                                                                                                                                                                                              
  Cancer tissue:                                                                                                                                                                                                                                               
  Negative maspin (T2 → T4 positive?)                                                                                                                                                                                                                          
  Lung cancer                                              Normal tissue: positive maspin                                                                              Positive nucleus = better prognosis vs nuclear and positive cytoplasm                   Positive maspin = better prognosis
  Lung cancer = less positive maspin                                                                                                                                                                                                                           
  Ovarian cancer                                           Normal tissue: Negative maspin                                                                              Positive nucleus (rare) = better prognosis                                              Positive maspin = better/worse prognosis depending of localization and of epigenetic modification
  Early stage                                                                                                                                                                                                                                                  
  Ovarian cancer = positive maspin                                                                                                                                                                                                                             
  Metastic cancer = less positive                                                                                                                                                                                                                              
  Colorectal cancer                                        Normal tissue: negative maspin                                                                              Positive nucleus = worse prognosis                                                      Positive maspin = better prognosis, positive response to 5FU therapy
  Dysplasia and cancer = positive maspin                                                                                                                                                                                                                       
  Positive cytoplasm better prognosis                                                                                                                                                                                                                          
  Gastric cancer                                           Normal tissue: positive maspin                                                                              Positive nucleus and positive cytoplasm = better prognosis vs only positive cytoplasm   Positive maspin = better prognosis
  Cancer tissue: negative maspin                                                                                                                                                                                                                               
  Pancreatic cancer                                        Normal tissue: negative maspin                                                                                                                                                                      Positive maspin = worse prognosis
  Pan In1, Pan In2 = negative maspin                                                                                                                                                                                                                           
  Pan In3 and cancer invasive tissue = positive maspin                                                                                                                                                                                                         
  Gallbladder cancer                                       Normal tissue: dysplasia = negative maspin intestinal metastasia and cancer = positive maspin                                                                                                        
  Head and neck cancer                                                                                                                                                 Positive nucleus = better prognosis                                                     Positive maspin = better prognosis
  Thyroid cancer                                           Normal tissue adenomas and follicular carcinoma = negative maspin/+ papillary carcinoma = positive maspin                                                                                           Positive maspin = better prognosis
  Anaplastic and poorly differentiated = negative maspin                                                                                                                                                                                                       
  Melanoma malignant                                       Normal tissue: positive maspin                                                                              Positive nucleus = better prognosis                                                     Positive maspin = better prognosis
  Melanoma = positive maspin                                                                                                                                                                                                                                   
                                                           Metastatic melanoma = negative maspin                                                                                                                                                                

The correlation between the expression of maspin and clinical parameters is different depending on the type of tumor. It is likely that the lack of standardization in assessing the positivity of maspin subcellular level and the need for more studies about it can explain and permit the interpretation of differences. It would be more helpful to evaluate the expression of maspin only as a positive nucleus-cytoplasm to ensure greater uniformity of results.
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